Assessment of the Toxicity and the Stability of Saeng Mak San by Using Repeated Intravenous Injections in Sprague-Dawley Rats
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Objectives: This study used repeated intravenous injections of Saeng Maek San (SMS) injection in Sprague-Dawley (SD) rats to assess the toxicity and the stability of SMS. Methods: Six-week-old male and female SD rats reared by Orient bio Inc were chosen for this pilot study. They were randomly split into four groups: Group 1 (G1), the control group (0.3 mL of normal saline solution/day/ animal), and Groups 2, 3 and 4 (G2, G3 and G4), the experimental groups (0.1, 0.2 and 0.3 mL/day/animal of SMS), respectively. Each animal received an intravenous injection of SMS once a day for four weeks. Clinical signs, body weight changes, and food consumption were monitored during the observation period, and urinalysis and hematology were conducted after four weeks of SMS or saline administration. Results: No deaths occurred in any of the four groups during the observation period. Compared to the control group, male and female rats in groups 3 and 4 (0.2 and 0.3 mL/animal/day) showed hemoglobinuria, but the low-dosage group (G2, 0.1 mL/animal/day) showed no significant changes in the clinical signs test. No significant changes due to SMS were observed in the experimental groups regarding body weight changes, food consumption urinalysis, or hematology. Conclusion: During this study, no mortalities were observed in any of the experimental groups and no hemoglobinuria was observed in the low dosage group (0.1 mL/animal/day) while it was intermittently observed in groups 3 and 4 (0.2 and 0.3 mL/animal/day). Thus, we suggest that the no-observed adverse-effect level (NOAEL) is 0.1 mL/animal/day in male and female SD rats.
Abstract
Objectives: This study used repeated intravenous injections of Saeng Maek San (SMS) injection in Sprague-Dawley (SD) rats to assess the toxicity and the stability of SMS. Methods: Six-week-old male and female SD rats reared by Orient bio Inc were chosen for this pilot study. They were randomly split into four groups: Group 1 (G1), the control group (0.3 mL of normal saline solution/day/ animal), and Groups 2, 3 and 4 (G2, G3 and G4), the experimental groups (0.1, 0.2 and 0.3 mL/day/animal of SMS), respectively. Each animal received an intravenous injection of SMS once a day for four weeks. Clinical signs, body weight changes, and food consumption were monitored during the observation period, and urinalysis and hematology were conducted after four weeks of SMS or saline administration. Results: No deaths occurred in any of the four groups during the observation period. Compared to the control group, male and female rats in groups 3 and 4 (0.2 and 0.3 mL/animal/day) showed hemoglobinuria, but the low-dosage group (G2, 0.1 mL/animal/day) showed no significant changes in the clinical signs test. No significant changes due to SMS were observed in the experimental groups regarding body weight changes, food consumption urinalysis, or hematology. Conclusion: During this study, no mortalities were observed in any of the experimental groups and no hemoglobinuria was observed in the low dosage group (0.1 mL/animal/day) while it was intermittently observed in groups 3 and 4 (0.2 and 0.3 mL/animal/day). Thus, we suggest that the no-observed adverse-effect level (NOAEL) is 0.1 mL/animal/day in male and female SD rats.
참고문헌 (12)
- Korean pharmacopuncture institute, "Pharmacopuncture therapy guidelines", pp.143~ (1999), Hansung printing
- Joo HJ, "Researches on pharmacopuncture", Korea Institute of Oriental medicine, 5, pp.193~210 (1995)
- Konishi T, "Brain oxidative stress as basic target of antioxidant traditional oriental medicines", Neurochem Res, 34(4), pp.711~716 (2009)
- Chen CY, "Shengmai injection, a traditional Chinese patent medicine, for intradialytic hypotension: a systematic review and meta-analysis", Evid Based Complement Alternat Med, 2013 (2013)
- Zhang YC, "Effect of shengmai injection on cardiac function and inflammatory reaction in patients with acute coronary syndrome", Chin J Integr Med, 14(2), pp.107~110 (2008)
- Pou Kuan Leong, "Long-Term Treatment with Shengmai San-Derived Herbal Supplement (Wei Kang Su) Enhances Antioxidant Response in Various Tissues of Rats with Protection Against Carbon Tetrachloride Hepatotoxicity", Journal of Medicinal Food, 13(2), pp.427~438 (2010), 한국식품영양과학회
- Wang L, "Prevention of oxidative injury in PC12 cells by a traditional Chinese medicine, Shengmai San, as a model of an antioxidant- based composite formula", Biol Pharm Bull, 26(7), pp.1000~1004 (2003)
- Nishida H, "Amyloid-beta-induced cytotoxicity of PC-12 cell was attenuated by Shengmai-san through redox regulation and outgrowth induction", J Pharmacol Sci, 104(1), pp.73~81 (2007)
- Yu JH, "Impact of shengmal injection on changes of immunological function in patients after cardiopulmonary bypass", Zhongguo Zhong Xi Yi Jie He Za Zhi, 29(4), pp.317~321 (2009)
- Zhou Q, "Shengmai (a traditional Chinese herbal medicine) for heart failure", Cochrane Database Syst Rev, 14(4) (2014)
- Wang NL, "Shengmai San, a Chinese herbal medicine protects against rat heat stroke by reducing inflammatory cytokines and nitric oxide formation", J Pharmacol Sci, 98(1), pp.1~7 (2005)
- Seo TB, "Shengmai-san-mediated enhancement of regenerative responses of spinal cord axons after injury in rats", J Pharmacol Sci, 110(4), pp.483~492 (2009)